Brussels, Belgium, 10 November 2009 at 8:30 am CET - UCB today
announced the appointment of Ismail Kola, Executive Vice President,
UCB & President of UCB New Medicines(TM),UCB's discovery research
through to 'proof of concept' organization. Ismail Kola will join
UCB's Executive Committee with effect from November 23, 2009.

Roch Doliveux, Chief Executive Officer of UCB said, "We are pleased
to announce Ismail's appointment to lead our internal and external
discovery of new medicines to treat patients with severe diseases.
UCB is gaining a highly accomplished scientist with a track record of
success in academia and the biopharma field. I am confident that
Ismail will make major leaps to the development of UCB
NewMedicines(TM). His strong research and development background in
combination with solid commercial understanding will move UCB
NewMedicines(TM) beyond its current achievements to deliver UCB's
breaktrough phase.''

For more then 20 years, Ismail Kola has created a bridge between the
scientific and academic worlds trough various projects funded by
renowned institutes such as the NHMRC (National Health & Medical
Research Council) Australia, the National Institutes of Health, USA
and Monash University in Australia. He has authored 159 technical
publications in scientific and medical journals of the highest
caliber, and is a named inventor on 12 patents. Under his leadership
numerous drugs have come to the market and many are now in late-stage
development.

Since March 2007, Dr. Kola has occupied the role of Senior
Vice-President, Discovery Research and Early Clinical Research &
Experimental Medicine, and Chief Scientific Officer at
Schering-Plough. He came to Schering Plough from Merck where in
January 2003 he was appointed Senior Vice President/Site Head, Basic
Research. Prior to that, Ismail was Vice President, Research, and
Global Head, Genomics Science and Biotechnology with Pharmacia
Corporation, and served as a consultant to SmithKline Beecham
Pharmaceuticals where he was also a member of the Genomics Advisory
Board.

As of 23 November 2009, UCB's Executive Committee, chaired by Roch
Doliveux, CEO, will have the following members, all of whom are
Executive Vice Presidents: Michele Antonelli, Fabrice Enderlin,
Ismail Kola, Iris Loew-Friedrich, Mark McDade, Detlef Thielgen and
Bob Trainor.


For further information

Nancy Nackaerts, External Communications, UCB
T +32.473.864.414, nancy.nackaerts@ucb.com

About NewMedicines(TM)
Encompassing discovery research activities through to proof of
concept, UCB NewMedicines(TM) is an innovative and externally
networked organisation established to secure the future pipeline and
deliver UCB's breakthrough products of the future.
A disseminated research organisation will maximise UCB's investment
in scientific and medical breakthroughs via a highly collaborative
approach to forming teams and projects to create new medicines. Based
on a 'hub' model of operation, UCB NewMedicines(TM) is located on two
key sites at Braine-l'Alleud, Belgium and Slough, UK. Operations at
these hubs focus on the therapeutic areas of CNS (Central Nervous
System) and Immunology with strong technology platforms underpinning
the research. The organisation houses leaders and experts who possess
the highest level skills to search, review, decide and transact on
all aspects of the portfolio in all functions.
Internal resources differentiate UCB whilst external resources are
accessed for routine activities or to provide specialist
complementary skills and capabilities. The organisation fully
embraces external networking to support our focus on the pipeline
delivery and breakthrough science.  Medics and patients inform
choices from the outset of projects.

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company
dedicated to the research, development and commercialization of
innovative medicines with a focus on the fields of central nervous
system and immunology disorders. Employing approximately 10 000
people in over 40 countries, UCB generated revenue of 3.6 billion
euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.

For the pdf-version of this press release, please click on the link
below:

hugin.info/133973/R/1353778/327974.pdf


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.